HealthQuill Pharma
Harvard University has rejected demands from US President Donald Trump’s administration that threaten $9 billion in research funding.
Drugs Health Pharma

Harvard rejects Trump’s demands that threaten $9b research funding

HQ Team April 15, 2025: Harvard University has rejected demands from US President Donald Trump’s administration that threaten $9 billion in research funding..

Read More
Cambridge researchers have invented a device to record heart sounds accurately and diagnose coronary valve diseases better than traditional stethoscopes.
Health Medical Pharma

Cambridge develops handheld device to detect faulty heart valves

HQ Team April 13, 2025: Cambridge researchers have invented a device to record heart sounds accurately and diagnose coronary valve diseases better than.

Read More
Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its coronary intravascular catheter for treating blocked arteries, according to a statement.
Health Medical Pharma

J&J starts trial on coronary pressure wave catheter to clear artery blocks

HQ Team April 13, 2025: Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its.

Read More
A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is underway in US research institutions as the overall disease population is expected to reach 783 million people by 2045.
Health Pharma

Dexcom’s 15-day G7 sensor for glucose monitoring wins FDA nod

HQ Team April 11, 2025: For people living with diabetes, glucose sensors for monitoring sugar levels are a game changer. The present ones.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Pharma

Novartis bets $23b on US as pharma giants brace for tariff storm

Swati Mishra April 11, 2025: “We are prepared for shifts in the external environment and fully confident in our growth outlook,” Novartis CEO Vas.

Read More
Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of injectable treatments for people living with obesity and chronic diseases.
Drugs Medical Pharma

Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil

HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.

Read More
The United Nations has warned that “unprecedented” global aid cuts could derail a three-year trend of a 40% decline in maternal deaths as one maternal death occurred every two minutes worldwide in 2023.
Drugs Health Pharma

Maternal mortality rates may fail UN goal, global aid cuts the main culprit 

HQ Team April 9, 2025: The United Nations has warned that “unprecedented” global aid cuts could derail a three-year trend of a 40%.

Read More
Marathons may affect the brain causing the organ to eat itself to make up for fuel lost during the run, and the effect is reversible, according to Spanish researchers.
Health Medical Pharma

Marathoner’s brain eats itself, effect is reversible: Spanish researchers

HQ Team April 6, 2025: Marathons may affect the brain causing the organ to eat itself to make up for fuel lost during.

Read More
AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from the European Union.
Drugs Health Pharma

AstraZeneca’s lung cancer drug combination gets EU approval 

HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.

Read More
Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European Union, the companies announced.
Drugs Medical Pharma

EU green lights AstraZeneca, Daiichi’s treatment for breast cancer

HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.

Read More